A Multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancer

A Multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancer - Phase II study of S-1 plus bevacizumab

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007386

Enrollment

Registered

2012-02-27

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanved non-squamous non-small cell lung cancer

Interventions

S-1 Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Written informed consent before initiation of study-related procedures. (2)Patients suitable for inclusion in the study according to the opinion of the investigator. (3)Histologically or cytologically confirmed non-squamous non-small cell lung cancer, stage IIIB or IV, previously treated with platinum-based chemotherapy as a first line treatment. (4)Age: 20 years<= (5)With one or more measurable disease based on RECIST (6)Performance status (ECOG) : 0-2 (7)Adequate function of vital organs (8)Expected survival over 3 months

Exclusion criteria

Exclusion criteria: (1)Squamous cell carcinoma (2)Previously untreated with platinum-based chemotherapy as a first line treatment (3)Discontinued bevacizumab due to its toxicity during a first line treatment (4)Severe complications (5)Symptomatic brain metastasis (6)Tumor cavitation (7)History or complication of hemoptysis with 2.5mL per time or more (8)Continuouis bloody phlegm more than 1 week. History or complication of bloody phlegm treated with continuous oral hemostatic agent. History or complication of bloody phlegm treated with infusional hemostatic agent. (9)Uncontrollable hypertension (10)History of GI perforation (11)Planning of surgery (12)Active concomitant malignancy (13)Severe drug allergy (14)Pregnancy or lactation (15)Severe psychological illness (16)History of thoracic radiotherapy (17)Systemic steroid treatment

Design outcomes

Secondary

Measure	Time frame
safety, response rate, overall survival	—

Primary

Measure	Time frame
progression free survival	—

Countries

Japan

Contacts

Public ContactKazuhiko Yamada

Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine

kayamada@med.kurume-u.ac.jp0942-31-7560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026